Monofree (Dexamethasone Phosphate)

Dexamethasone phosphate, the active ingredient in Monofree, is a corticosteroid presented as a sterile ophthalmic solution for ocular use. It is employed to manage inflammatory conditions of the eye, reducing swelling, pain, and immune‑mediated reactions in patients requiring topical therapy.

GNH USA supplies Monofree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monofree, a corticosteroid, is applied to ocular tissues to control inflammation and immune‑mediated eye disorders.

- Post‑operative ocular inflammation: reduces swelling and discomfort after eye surgery. - Anterior uveitis: diminishes inflammatory cell infiltrate and pain in the anterior chamber. - Allergic conjunctivitis: alleviates redness, itching, and edema caused by allergic reactions. - Corneal graft rejection: suppresses immune response to improve graft survival. - Ocular edema: decreases fluid accumulation in the retina or macula associated with inflammatory processes.

Adverse reactions may occur with ocular corticosteroid use and should be monitored.

Common Side Effects: - Transient ocular irritation or burning sensation. - Increased intra‑ocular pressure. - Blurred vision. - Mild cataract formation with prolonged use. - Conjunctival hyperemia.

Serious or Rare Side Effects: - Secondary ocular infection (bacterial or fungal). - Glaucoma due to sustained pressure elevation. - Delayed wound healing after surgery. - Systemic absorption leading to adrenal suppression. - Severe hypersensitivity or allergic reaction.

Monofree requires careful use to minimize risks.

- Monitor intra‑ocular pressure: check regularly during therapy. - Limit duration: use the shortest effective course to avoid cataract formation. - Avoid in active ocular infection: corticosteroids can exacerbate infections. - Caution in diabetic patients: may affect blood glucose control. - Pregnancy and lactation: use only if clearly needed and prescribed. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Potential drug interactions should be evaluated before initiating therapy.

Major Interactions (Avoid): - Systemic corticosteroids: additive systemic glucocorticoid effects. - Antiviral agents for herpes simplex: may increase risk of viral reactivation. - Non‑steroidal anti‑inflammatory eye drops: heightened risk of corneal melting.

Moderate Interactions (Monitor Closely):\n- Anticholinergic ophthalmic drops: may reduce efficacy of dexamethasone. - Beta‑blocker eye drops: possible additive effect on intra‑ocular pressure. - CYP3A4 inhibitors: may increase systemic exposure if significant absorption occurs.